In a strategic expansion move, Omega Hospitals supported by Morgan Stanley Private Equity has acquired Cytecare Hospitals, marking its entry into the Bengaluru oncology market. Cytecare, established in 2016 and situated on the international airport road in North Bengaluru, is a 150-bed NABH-accredited oncology centre known for its research-oriented and service-driven model.

Dr Mohana Vamsy, Managing Director of Omega Hospitals, commented: “This acquisition is a significant milestone for Omega, providing entry into an important geography outside our core regions of Andhra Pradesh & Telangana. Over the last two years we have worked on creating pan-India centres of excellence  and now Bengaluru is part of that expansion strategy.”

From the investor perspective, Prateek Bhurat of Morgan Stanley Private Equity said the deal recognises Cytecare’s strategic location, strong clinical talent and growth potential. He added that the facility will be developed into Omega’s quaternary cancer-care centre, with investment earmarked for top clinical hires and high-end medical equipment.

The acquisition comes on the heels of a ~₹500-crore investment by Morgan Stanley in Omega Hospitals in June 2024, aimed at fuelling its pan-India expansion. The company currently operates 14 hospitals with around 2,000 beds across five states. The Bengaluru acquisition underscores its ambition to broaden its footprint into key metropolitan markets.

Going forward, Omega plans to integrate Cytecare into its network, enhance clinical services, boost research and scale up advanced oncology treatments. The move carries implications for the Indian corporate oncology market, indicating increasing consolidation and focus on high-quality, multi-modal cancer care.